COMT inhibitors in Parkinson's disease.
Identifieur interne : 000046 ( Ncbi/Curation ); précédent : 000045; suivant : 000047COMT inhibitors in Parkinson's disease.
Auteurs : J. Rivest [Canada] ; C L Barclay ; O. SuchowerskySource :
- The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques [ 0317-1671 ] ; 1999.
English descriptors
- KwdEn :
- MESH :
- chemical , metabolism : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Catechols, Enzyme Inhibitors.
- chemical : Catechol O-Methyltransferase Inhibitors.
- drug therapy : Parkinson Disease.
- Clinical Trials as Topic, Humans.
Abstract
The COMT inhibitors, tolcapone and entacapone, are a new class of Parkinson's medications. By inhibiting the enzyme catechol-o-methyl-transferase (COMT), they prevent peripheral degradation of levodopa, allowing a higher concentration to cross the blood-brain barrier. Pharmacokinetic studies have shown that both tolcapone and entacapone significantly prolong the elimination half life, and increase the area under the curve of levodopa without increasing C max. Clinical studies with COMT inhibitors have shown benefit in both stable and fluctuating PD patients with improvement in motor function with lower levodopa doses. Fluctuating patients also had increased "on" time and reduced "wearing off". Side effects were most commonly related to increased dopaminergic stimulation. Specific side effects included diarrhea and elevated liver enzymes. The recent reports of three cases of fulminant hepatitis with the use of tolcapone has led many countries to remove this compound from their market. Concerns about a possible class effect should impose close monitoring of liver function tests with the use of any of the nitrocatechols.
PubMed: 10451758
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001691
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001691
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001691
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000046
Links to Exploration step
pubmed:10451758Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COMT inhibitors in Parkinson's disease.</title>
<author><name sortKey="Rivest, J" sort="Rivest, J" uniqKey="Rivest J" first="J" last="Rivest">J. Rivest</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre Universitaire de Santé de l'Estrie, Fleurimont, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre Universitaire de Santé de l'Estrie, Fleurimont, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barclay, C L" sort="Barclay, C L" uniqKey="Barclay C" first="C L" last="Barclay">C L Barclay</name>
</author>
<author><name sortKey="Suchowersky, O" sort="Suchowersky, O" uniqKey="Suchowersky O" first="O" last="Suchowersky">O. Suchowersky</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10451758</idno>
<idno type="pmid">10451758</idno>
<idno type="wicri:Area/PubMed/Corpus">001691</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001691</idno>
<idno type="wicri:Area/PubMed/Curation">001691</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001691</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001691</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001691</idno>
<idno type="wicri:Area/Ncbi/Merge">000046</idno>
<idno type="wicri:Area/Ncbi/Curation">000046</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">COMT inhibitors in Parkinson's disease.</title>
<author><name sortKey="Rivest, J" sort="Rivest, J" uniqKey="Rivest J" first="J" last="Rivest">J. Rivest</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre Universitaire de Santé de l'Estrie, Fleurimont, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre Universitaire de Santé de l'Estrie, Fleurimont, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barclay, C L" sort="Barclay, C L" uniqKey="Barclay C" first="C L" last="Barclay">C L Barclay</name>
</author>
<author><name sortKey="Suchowersky, O" sort="Suchowersky, O" uniqKey="Suchowersky O" first="O" last="Suchowersky">O. Suchowersky</name>
</author>
</analytic>
<series><title level="j">The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques</title>
<idno type="ISSN">0317-1671</idno>
<imprint><date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (metabolism)</term>
<term>Catechol O-Methyltransferase Inhibitors</term>
<term>Catechols (therapeutic use)</term>
<term>Clinical Trials as Topic</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Humans</term>
<term>Levodopa (metabolism)</term>
<term>Parkinson Disease (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Catechols</term>
<term>Enzyme Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Catechol O-Methyltransferase Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The COMT inhibitors, tolcapone and entacapone, are a new class of Parkinson's medications. By inhibiting the enzyme catechol-o-methyl-transferase (COMT), they prevent peripheral degradation of levodopa, allowing a higher concentration to cross the blood-brain barrier. Pharmacokinetic studies have shown that both tolcapone and entacapone significantly prolong the elimination half life, and increase the area under the curve of levodopa without increasing C max. Clinical studies with COMT inhibitors have shown benefit in both stable and fluctuating PD patients with improvement in motor function with lower levodopa doses. Fluctuating patients also had increased "on" time and reduced "wearing off". Side effects were most commonly related to increased dopaminergic stimulation. Specific side effects included diarrhea and elevated liver enzymes. The recent reports of three cases of fulminant hepatitis with the use of tolcapone has led many countries to remove this compound from their market. Concerns about a possible class effect should impose close monitoring of liver function tests with the use of any of the nitrocatechols.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000046 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000046 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:10451758 |texte= COMT inhibitors in Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:10451758" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonCanadaV1
This area was generated with Dilib version V0.6.29. |